Erie Times-News

Jaguar Health Participating in August 25-26 Animal Health Summit with Goal of Securing Collaboration to Expand Canalevia’s Indication to Treatment of General Diarrhea in Dogs

The Animal Health Summit, hosted by KC Animal Health Corridor, takes place August 25-26, 2025 in Kansas City, Missouri. “I’m pleased to report that Jaguar is currently in discussions with multiple ...
Nasdaq

Jaguar Health Celebrates National Pet Cancer Awareness Month: With its Supportive Cancer Care Drugs, Jaguar is Dedicated to the Health and Wellbeing of People and Dogs

Company's Canalevia®-CA1 (crofelemer delayed-release tablets) prescription drug is FDA conditionally approved for treatment of chemotherapy-induced diarrhea (CID) in dogs and is the first and only ...
Hosted on MSN

Jaguar Health to participate in 2025 Animal Health Summit

Jaguar Health (JAGX) is participating in the 2025 Animal Health Summit in support of the company’s goal of securing a collaboration to expand the indication of Canalevia from treatment of chemotherapy ...

Jaguar Health Awarded $240,000 FDA Grant in Support of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / January 2, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar”) today announced that it received notice from the U.S. Food and Drug Administration’s Center ...
Argus Leader

Jaguar Health Participating in August 25-26 Animal Health Summit with Goal of Securing Collaboration to Expand Canalevia’s Indication to Treatment of General Diarrhea in Dogs

“Specifically, our objective is to partner with an animal health company to achieve three parallel goals for Canalevia: Expand the U.S. indication from CID in dogs to treatment of general diarrhea in ...